https://orcid.org/0000-0001-9646-6208
References
- Visvesvara GS, Moura H, Schuster FL. Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunol Med Microbiol. 2007;50(1):1–26.
- Schuster FL, Visvesvara GS. Opportunistic amoebae: challenges in prophylaxis and treatment. Drug Resist Updat. 2004;7(1):41–51.
- Gastaut H, Naquet R, Poire R, et al. Treatment of status epilepticus with diazepam (Valium). Epilepsia. 1965;6(2):167–182.
- De Silva M, MacArdle B, McGowan M, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet. 1996;347(9003):709–713.
- Hung CC, Lin CJ, Chen CC, et al. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther Drug Monit. 2004;26(5):534–540.
- Anwar A, Rajendran K, Siddiqui R, et al. Clinically approved drugs against CNS diseases as potential therapeutic agents to target brain-eating amoebae. ACS Chem Neurosci. 2019;10(1):658–666.
- Singh S, Bharti N, Mohapatra PP. Chemistry and biology of synthetic and naturally occurring antiamoebic agents. Chem Rev. 2009;109(5):1900–1947.
- Rice CA, Colon BL, Chen E, et al. Discovery of repurposing drug candidates for the treatment of diseases caused by pathogenic free-living amoebae. PLoS Negl Trop Dis. 2020;14(9):e0008353.
- Soltow SM, Brenner GM. Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. Antimicrob Agents Chemother. 2007;51(1):23–27.
- Debnath A. Drug discovery for primary amebic meningoencephalitis: from screen to identification of leads. Expert Rev Anti Infect Ther. 2021;19(9):1099–1106.
- Mungroo MR, Khan NA, Anwar A, et al. Nanovehicles in the improved treatment of infections due to brain-eating amoebae. Int Microbiol. 2021;1–11. doi:https://doi.org/10.1007/s10123-021-00201-0
- Saeed BQ, Hussain K, Akbar N, et al. Nanovesicles containing curcumin hold promise in the development of new formulations of anti-Acanthamoebic agents. Mol Biochem Parasitol. 2021;247:111430.